This suggests that targeting mitochondrial Akt is a potential therapeutic approach to improve cardiac insulin-stimulated glucose oxidation in the setting of heart failure, obesity and diabetes, situations where the heart is insulin resistant. The gene discussed is AKT1; the disease is obesity due to melanocortin 4 receptor deficiency.